Research is exploring the potential of combining small-molecule targeted drugs with CAR-T cell therapy to treat hematologic lymphomas. The field of targeted therapy is advancing, with studies investigating various approaches, including epigenetic mechanisms and small non-coding RNAs. The development of new therapies, including those targeting specific mutations and immune mechanisms, may enhance the safety and efficacy of treatments for these cancers.